Table 1 Clinical and pathological characteristics in the training and validation cohorts
Characteristics | Training Cohort (n = 141) | Validation Cohort (n = 61) | P |
|---|---|---|---|
Age, mean ± SD | 55.1 ± 12.076 | 55.25 ± 10.779 | 0.935 |
Sex, n (%) | Â | Â | 0.346 |
Male | 84 (59.6) | 41 (67.2) | Â |
Female | 57 (40.4) | 20 (32.8) | Â |
Location, n (%) | Â | Â | 0.467 |
Antrum | 88 (62.4) | 37 (60.7) | Â |
Non-Antrum | 53 (37.6) | 24 (39.3) | Â |
Differentiation degree, n (%) | Â | Â | 0.87 |
Well differentiated | 5(3.5) | 2 (3.3) | Â |
Moderately differentiated | 39 (27.7) | 14 (23.0) | Â |
Poorly differentiated | 96 (68.8) | 45 (73.8) | Â |
Stage Groupings for pTNM, n (%) | Â | Â | 0.196 |
Stage I - II | 71 (50.4) | 26 (42.6) | Â |
Stage III | 70 (49.6) | 35 (57.4) | Â |
Dukes-MAC-like staging system, n (%) | Â | Â | 0.898 |
Stage A1 (T1N0) | 21 (14.9) | 6 (9.8) | Â |
Stage A2 (T1N1-3) | 4 (2.8) | 4 (6.6) | Â |
Stage B1 (T2N0) | 8 (5.7) | 4 (6.6) | Â |
Stage B2 (T2N1-3) | 14 (9.9) | 7 (11.5) | Â |
Stage C1 (T3N0) | 7 (5.0) | 0 (0.0) | Â |
Stage C2 (T3N1-3) | 19 (13.5) | 4 (6.6) | Â |
Stage D (T4N0-3) | 68 (48.2) | 36 (59.0) | Â |